Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma

American Journal of Gastroenterology

Volumn 94, Issue 3, 1999, Pages 650-654

  Nomura, Fumio ^a   Ishijima, Michikuni ^b   Kuwa, Katsuhiko ^b   Tanaka, Naomi ^b   Nakai, Toshiaki ^b   Ohnishi, Kunihiko ^b  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DECARBOXYPROTHROMBIN; LECTIN; VITAMIN K GROUP;

ARTICLE; CHEMOLUMINESCENCE; DIAGNOSTIC ACCURACY; ELECTROCHEMICAL ANALYSIS; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; IMMUNORADIOMETRIC ASSAY; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTHROMBIN DEFICIENCY;

BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CHEMILUMINESCENT MEASUREMENTS; FEMALE; HUMANS; IMMUNOASSAY; IMMUNORADIOMETRIC ASSAY; LIVER NEOPLASMS; MALE; PREDICTIVE VALUE OF TESTS; PROTEIN PRECURSORS; PROTHROMBIN; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0033048769     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(98)00811-9     Document Type: Article

References (22)

1. Okuda K. Early recognition of hepatocellular carcinoma. Hepatology 1986;6:729-38.
2. Taketa K, Sekiya C, Namiki M, et al. Lectin-reactive profiles of alpha-fetoprotein and its usefulness in the early diagnosis of hepatocellular carcinoma and related conditions. Gastroenterology 1990;99:508-18.
3. Sato Y, Nakata K, Kato Y, et al. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-feto-protein. N Engl J Med 1993;328:1802-6.
4. Liebman HA, Furie BC, Tong MJ, et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984;310:1427-31.
5. Fujiyama S, Motohara T, Sagara K, et al. Clinical evaluation of plasma prothrombin (PIVKA-II) in patients with hepatocellular carcinoma. Hepatogastroenterology 1986;33:201-5.
6. Okuda H, Obata H, Nakanishi T, et al. Production of abnormal prothrombin (des-gamma-carboxy prothrombin) by hepatocellular carcinoma. J Hepatol 1987;4:357-63.
7. Motohara K, Kuroki Y, Kan H, et al. Detection of vitamin K deficiency by use of an enzyme-linked immunosorbent assay for circulating abnormal prothrombin. Pediatr Res 1985;19: 354-7.
8. Naraki T, Watanabe K, Shimazuru Y, et al. Development and evaluation of the EIA kit for detection of PIVKA-II using double antibody sandwich system: Monoclonal antibody to PIVKA-II and polyclonal antibody to prothrombin. Clin Immunol 1986;18:479-92.
9. Fujiyama S, Morishita T, Hashiguchi O, et al. Plasma abnormal prothrombin (des-gamma-carboxy prothrombin) as a marker of hepatocellular carcinoma. Cancer 1988;61:1621-8.
10. Tanabe Y, Ohnishi K, Nomura F, et al. Plasma abnormal prothrombin levels in patients with small hepatocellular carcinoma. Am J Gastroenterol 1988;83:1386-9.
11. Kasahara A, Hayashi N, Fusamoto H, et al. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes. Dig Dis Sci 1991;38:2170-6.
12. Saitoh S, Ikeda K, Koida I, et al. Serum des-gamma-carboxyprothrombin concentration determined by the avidin-biotin complex method in small hepatocellular carcinomas. Cancer 1994;74:2918-23.
13. Nomura F, Ishijima M, Horikoshi A, et al. Determination of serum des-gamma-carboxy prothrombin levels in patients with small-sized hepatocellular carcinoma: Comparison of the conventional enzyme immunoassay and two modified methods. Am J Gastroenterol 1996;91:1380-3.
14. Creedon KA, Suttie JW. Effect of N-methyl-thiotetrazole on vitamin K epoxide reductase. Thrombosis Res 1986;44:147-53.
15. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-77.
16. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
17. Weitz LC, Liebman HA. Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: A critical review. Hepatology 1993;18:900-7.
18. Shimada M, Takenaka K, Fujiwara Y, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma. Cancer 1996;78:2094-2100.
19. Aoyagi Y, Suzuki Y, Isemura M, et al. The fucosylation index of alpha-fetoprotein and its usefulness in the early diagnosis of hepatocellular carcinoma. Cancer 1988;61:769-74.
20. Grosley BM, Hirchauer C, Chambrette B, et al. Specific measurement of hypocarboxylated prothrombin in plasma or serum and application to the diagnosis of hepatocellular carcinoma. J Lab Clin Med 1996;127:553-64.
21. Nakao A, Taniguchi K, Inoue S, et al. Clinical application of a new monoclonal antibody (19B7) against PIVKA-II in the diagnosis of hepatocellular carcinoma and pancreatobiliary malignancies. Am J Gastroenterol 1997;92:1031-4.
22. Oka H, Tamori A, Kuroki T, et al. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994;19: 61-6.